Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector

Abstract

Inherited retinal degenerations are caused by mutations in >250 genes that affect photoreceptor cells or the retinal pigment epithelium and result in vision loss. For autosomal recessive and X-linked retinal degenerations, significant progress has been achieved in the field of gene therapy as evidenced by the growing number of clinical trials and the recent commercialization of the first gene therapy for a form of congenital blindness. However, despite significant efforts to develop a treatment for the most common form of autosomal dominant retinitis pigmentosa (adRP) caused by >150 mutations in the rhodopsin (RHO) gene, translation to the clinic has stalled. Here, we identified a highly efficient shRNA that targets human (and canine)RHOin a mutation-independent manner. In a single adeno-associated viral (AAV) vector we combined this shRNA with a humanRHOreplacement cDNA made resistant to RNA interference and tested this construct in a naturally occurring canine model ofRHO-adRP. Subretinal vector injections led to nearly complete suppression of endogenous canineRHORNA, while the humanRHOreplacement cDNA resulted in up to 30% of normal RHO protein levels. Noninvasive retinal imaging showed photoreceptors in treated areas were completely protected from retinal degeneration. Histopathology confirmed retention of normal photoreceptor structure and RHO expression in rod outer segments. Long-term (>8 mo) follow-up by retinal imaging and electroretinography indicated stable structural and functional preservation. The efficacy of this gene therapy in a clinically relevant large-animal model paves the way for treating patients withRHO-adRP.